I-CBP112 is primarily used in biomedical research as a selective inhibitor of the bromodomain and extra-terminal (BET) family proteins, particularly targeting CBP (CREB-binding protein) and its paralog p300. It is employed to study epigenetic regulation of gene expression, especially in the context of inflammation, cancer, and cellular differentiation. By disrupting the interaction between CBP/p300 and acetylated histones, I-CBP112 modulates the transcription of key genes involved in tumor growth and immune responses. It has shown potential in preclinical studies for hematological malignancies and solid tumors, where dysregulation of BET proteins plays a critical role. Additionally, it serves as a tool compound for validating CBP/p300 as therapeutic targets in various disease models.